Abstract
Oxindole derivatives 3-25 have been synthesized from commercially available oxindole by refluxing with different aromatic aldehydes in good yields. Their in vitro antiglycation potential has been evaluated. They showed a varying degree of antiglycation activity with IC50 values ranging between 150.4 - 856.7 µM. 3-[(3-Chlorophenyl)methylidene]- 1,3-dihydro-2H-indol-2-one (IC50 = 150.4 ± 2.5 µM) is the most active compound among the series, better than the standard rutin with an IC50 value 294.5 ± 1.50 µM. The structures of the compounds were elucidated by 1H-NMR and mass spectroscopy and elemental analysis. A limited structure-activity relationship has been developed.
Keywords: Oxindole, benzaldehydes, antiglycation, rutin, AGEPs.
Medicinal Chemistry
Title:Oxindole Derivatives: Synthesis and Antiglycation Activity
Volume: 9 Issue: 5
Author(s): Khalid Mohammed Khan, Momin Khan, Nida Ambreen, Muhammad Taha, Fazal Rahim, Saima Rasheed, Sumayya Saied, Humaira Shafi, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Oxindole, benzaldehydes, antiglycation, rutin, AGEPs.
Abstract: Oxindole derivatives 3-25 have been synthesized from commercially available oxindole by refluxing with different aromatic aldehydes in good yields. Their in vitro antiglycation potential has been evaluated. They showed a varying degree of antiglycation activity with IC50 values ranging between 150.4 - 856.7 µM. 3-[(3-Chlorophenyl)methylidene]- 1,3-dihydro-2H-indol-2-one (IC50 = 150.4 ± 2.5 µM) is the most active compound among the series, better than the standard rutin with an IC50 value 294.5 ± 1.50 µM. The structures of the compounds were elucidated by 1H-NMR and mass spectroscopy and elemental analysis. A limited structure-activity relationship has been developed.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Khan Momin, Ambreen Nida, Taha Muhammad, Rahim Fazal, Rasheed Saima, Saied Sumayya, Shafi Humaira, Perveen Shahnaz and Choudhary Iqbal Muhammad, Oxindole Derivatives: Synthesis and Antiglycation Activity, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050007
DOI https://dx.doi.org/10.2174/1573406411309050007 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation
Current Drug Targets Role of Cytokines and Trophic Factors in the Pathogenesis of Diabetic Retinopathy
Current Diabetes Reviews Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design InhaledInsulin: A Novel and Non-Invasive Way for Insulin Administration?
Current Drug Safety XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Genome-Scale Technologies Foster Advances in Neurological and Behavioral Research
Current Psychiatry Reviews Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Common Themes in RNA Subcellular Transport, Stress Granule Formation and Abnormal Protein Aggregation
Current Chemical Biology Role of Zinc and Lysosomal Enzymes in Type 2 Diabetes Mellitus with Periodontitis
Current Nutrition & Food Science